Study identifier:D9289R00001
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Real-life treatment outcomes of ravulizumab in Polish patients with paroxysmal nocturnal hemoglobinuria (PNH). Prospective and retrospective, multicenter, non-interventional study.
Paroxysmal nocturnal haemoglobinuria
N/A
No
Ravulizumab
All
40
Observational
18 Years - n/a
Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Sept 2024 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|---|
Ravulizumab group Open-label | - |